Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulodexide for chronic primary venous disease of the lower extremities
2021-002311-64Phase 3Terminated
- Sponsor
- Alfasigma
- Start
- Oct 2021
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic venous disease (CVD) and venous stasis comparing Sulodexide with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Started Oct 2021; status: terminated.
02
Drugs
sulodexide
03
Conditions
chronic venous disease (CVD)venous stasis
Beyond the preview
Go deeper on 2021-002311-64.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002311-64.